Literature DB >> 17785561

Classification based on the combination of molecular and pathologic predictors is superior to molecular classification on prognosis in colorectal carcinoma.

Fangying Xu1, Fenjuan Wang, Meijuan Di, Qiong Huang, Min Wang, Hu Hu, Yisen Jin, Jiankang Dong, Maode Lai.   

Abstract

PURPOSE: Classification based on a combination of molecular and pathologic predictors had never been done using hierarchical cluster analysis. For this purpose, we identified prognostic classification based on molecular predictors, pathologic and molecular predictors, and compared their respective prognostic efficacy together with that of tumor-node-metastasis (TNM) stage. Moreover, we investigated the prognostic significance of molecular classification in different TNM stage. EXPERIMENTAL
DESIGN: Six pathologic predictors (p) and 13 immunohistochemical predictors (m) were investigated in 221 colorectal carcinomas. Unsupervised hierarchical clustering analysis was done to group the data. Survival analysis was done by Kaplan-Meier method and log-rank test, and by multivariate COX proportional hazard model.
RESULTS: Six pathologic predictors and four molecular predictors were of significant prognostic value (P <or= 0.05). One molecular predictor showed a trend toward significance (P = 0.085). Hierarchical clustering analysis was done based on different combinations (5p, 13m, 5m, 5p13m, and 5p5m), and distinct groups were produced except 5p (the TNM stage was excluded). Groups identified by 5m (P = 0.053) and 5p5m (P = 0.000) showed significant differences in prognosis. Groups identified by 5p5m and TNM stage were confirmed as the independent prognostic factors in a multivariate COX proportional hazard model. Moreover, groups identified by 5m could predict different prognoses in patients with stage II disease.
CONCLUSIONS: Classification based on pathologic and immunohistochemical predictors is superior to that based only on molecular predictors on prognosis. Classification based on 5m could identify additional different prognoses in patients with stage II disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17785561     DOI: 10.1158/1078-0432.CCR-07-0597

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

1.  Phosphorylated CXCR4 expression has a positive prognostic impact in colorectal cancer.

Authors:  B Weixler; F Renetseder; I Facile; N Tosti; E Cremonesi; A Tampakis; T Delko; S Eppenberger-Castori; A Tzankov; G Iezzi; C Kettelhack; S D Soysal; U von Holzen; G C Spagnoli; L Terracciano; L Tornillo; Raoul A Droeser; S Däster
Journal:  Cell Oncol (Dordr)       Date:  2017-09-21       Impact factor: 6.730

2.  Novel molecular classification of colorectal cancer and correlation with survival.

Authors:  Fayaz Hussain Mangi; Tanweer Ahmed Shaikh; Daniele Soria; Ali Muhammad Waryah; Ikram Din Ujjan; Jawaid Naeem Qureshi; Binafsha Manzoor Syed
Journal:  Saudi J Biol Sci       Date:  2022-03-10       Impact factor: 4.052

3.  AC133 expression associated with poor prognosis in stage II colorectal cancer.

Authors:  Xiaofang Ying; Jiangxue Wu; Xiangqi Meng; Yufang Zuo; Qing Xia; Jinou Chen; Yanfen Feng; Ranyi Liu; Liren Li; Wenlin Huang
Journal:  Med Oncol       Date:  2013-01-16       Impact factor: 3.064

4.  HSP60, a protein downregulated by IGFBP7 in colorectal carcinoma.

Authors:  Wenjing Ruan; Yinghong Wang; Yu Ma; Xiaoming Xing; Jie Lin; Jing Cui; Maode Lai
Journal:  J Exp Clin Cancer Res       Date:  2010-04-30

5.  p42.3: a promising biomarker for the progression and prognosis of human colorectal cancer.

Authors:  Xiao-Sun Yuan; Yi Zhang; Xiao-Ya Guan; Bin Dong; Min Zhao; Lin-Lin Mao; You-Yong Lu; Xiu-Yun Tian; Chun-Yi Hao
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-11       Impact factor: 4.553

Review 6.  Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7.

Authors:  Aïssata Aimée Goïta; Dominique Guenot
Journal:  Cancers (Basel)       Date:  2022-04-02       Impact factor: 6.639

7.  Reassessment of CXCR4 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2.

Authors:  Thomas Fischer; Falko Nagel; Stefan Jacobs; Ralf Stumm; Stefan Schulz
Journal:  PLoS One       Date:  2008-12-31       Impact factor: 3.240

8.  Preoperative serum CA 72.4 as prognostic factor of recurrence and death, especially at TNM stage II, for colorectal cancer.

Authors:  Daniel Ayude; Francisco Javier Rodríguez-Berrocal; José Ayude; Sonia Blanco-Prieto; Lorena Vázquez-Iglesias; Marta Vázquez-Cedeira; María Páez de la Cadena
Journal:  BMC Cancer       Date:  2013-11-12       Impact factor: 4.430

9.  The role of tissue and serum carcinoembryonic antigen in stages I to III of colorectal cancer-A retrospective cohort study.

Authors:  Guojun Tong; Wei Xu; Guiyang Zhang; Jian Liu; Zhaozheng Zheng; Yan Chen; Pingping Niu; Xuting Xu
Journal:  Cancer Med       Date:  2018-10-09       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.